Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 6,067 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched control Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Momentary Coping Prompts and Hair Steroids in College Students

NCT07782398
View directory record Official record
Conditions
Emotional Regulation, Alcohol Drinking in College, Emotional Eating, Aggression
Interventions
Momentary coping prompt, Active control message
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 22 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 10:38 AM EDT
Withdrawn Phase 2 Interventional

A Study of JNJ-64304500 in Participants With Alopecia Areata

NCT04740970
View directory record Official record
Conditions
Alopecia Areata
Interventions
JNJ-64304500, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Tampa, Florida • Plainfield, Indiana • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 25, 2026, 10:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Non-invasive Clinical Pectus Index as a Measurement of Severity in Pectus

NCT02552186
View directory record Official record
Conditions
Pectus Excavatum
Interventions
Caliper measurement
Other
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
11 Years to 21 Years
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 25, 2026, 10:38 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis

NCT05132569
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Tolebrutininb, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Boca Raton, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 25, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction

NCT00549939
View directory record Official record
Conditions
Neurogenic Urinary Bladder
Interventions
Alfuzosin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 16 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 25, 2026, 10:38 AM EDT
Withdrawn No phase listed Observational

Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making

NCT02158754
View directory record Official record
Conditions
Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases, CAD, CVD, Coronary Heart Disease, CHD
Interventions
Corus CAD (ASGES)
Diagnostic Test
Lead sponsor
CardioDx
Industry
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Rutherford, New Jersey • Wake Forest, North Carolina • Youngstown, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 25, 2026, 10:38 AM EDT
Completed Phase 2 Interventional

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)

NCT01674361
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Bitopertin, Placebo, SSRI
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
27
States / cities
Oceanside, California • Stanford, California • New Haven, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 25, 2026, 10:38 AM EDT
Recruiting Phase 3 Interventional

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

NCT05918861
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Dalcetrapib, Placebo
Drug
Lead sponsor
DalCor Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
186
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 25, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects

NCT04680429
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RP7214, Placebo
Drug
Lead sponsor
Rhizen Pharmaceuticals SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Las Vegas, Nevada • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 25, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation

NCT01161537
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-770, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 25, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

NCT00670930
View directory record Official record
Conditions
Allergic Asthma
Interventions
omalizumab at a dose of 0.016mg/kg/IU/mL, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Denver, Colorado • St Louis, Missouri • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 25, 2026, 10:38 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

NCT07321873
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
JNJ-88545223, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Searcy, Arkansas • Huntington Beach, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect

NCT03627494
View directory record Official record
Conditions
Muscular Dystrophies
Interventions
GSK3439171A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 25, 2026, 10:38 AM EDT
Completed Phase 2Phase 3 Interventional

Diclofenac Patch for Treatment of Mild to Moderate Tendonitis or Bursitis

NCT00640939
View directory record Official record
Conditions
Rotator Cuff Tendonitis, Bicipital Tendonitis, Subdeltoid Bursitis of the Shoulder, Subacromial Bursitis of the Shoulder, Medial Epicondylitis of the Elbow, Lateral Epicondylitis of the Elbow, DeQuervain's Tenosynovitis of the Wrist
Interventions
diclofenac sodium, Matching Placebo
Drug
Lead sponsor
Cerimon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2008 · Synced Oct 25, 2026, 10:38 AM EDT
Not listed Not applicable Interventional

Get Going: Accelerometer-Based Intervention to Promote Physical Activity in Frail Older Adults

NCT02635477
View directory record Official record
Conditions
Coronary Artery Disease, Heart Failure
Interventions
Intervention, Control
Behavioral
Lead sponsor
American College of Cardiology
Other
Eligibility
70 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 25, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

NCT04169373
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
41
States / cities
Flagstaff, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 25, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00763451
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 25, 2026, 10:38 AM EDT
Completed Not applicable Interventional

A Controlled Study to Evaluate the Effects of a Topical Cream on Symptoms of Arthritis, Joint, and Muscle Pain

NCT07767669
View directory record Official record
Conditions
Arthritis, Joint Pain, Muscle Pain, Musculoskeletal Pain, Joint Stiffness
Interventions
Intervention (Saje Pain Release Joint & Arthritis Cream), Placebo Comparator
Dietary Supplement
Lead sponsor
Saie Beauty
Industry
Eligibility
20 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 25, 2026, 10:38 AM EDT
Completed No phase listed Observational

Change in Pain With Virtual Reality-augmented Remote Rehabilitative Care

NCT05253157
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Virtual Reality Augmented remote rehabilitation
Other
Lead sponsor
XRHealth USA Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 25, 2026, 10:38 AM EDT
Recruiting Phase 2 Interventional

Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis

NCT04373473
View directory record Official record
Conditions
Adults With Ulcerative Colitis
Interventions
PRIM-DJ2727, Placebos
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 25, 2026, 10:38 AM EDT
Not yet recruiting Phase 2 Interventional

LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)

NCT07886554
View directory record Official record
Conditions
Sarcoidosis Associated Pulmonary Hypertension
Interventions
Placebo, LAM-001
Drug
Lead sponsor
IRulya Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

NCT04023994
View directory record Official record
Conditions
Alzheimers Disease
Interventions
RO7126209, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 25, 2026, 10:38 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

NCT02291237
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Eleclazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 25, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

NCT04442503
View directory record Official record
Conditions
Depression, Postpartum
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
68
States / cities
Scottsdale, Arizona • Bentonville, Arkansas • Anaheim, California + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 25, 2026, 10:38 AM EDT